Clinical efficacy and safety observation of Bushen Zhuangjin Decoction in the treatment of early and middlestage knee osteoarthritis

注册号:

Registration number:

ITMCTR2024000094

最近更新日期:

Date of Last Refreshed on:

2024-06-06

注册时间:

Date of Registration:

2024-06-06

注册号状态:

Registration Status:

预注册

Prospective registration

注册题目:

加味补肾壮筋汤治疗早中期膝骨关节炎的临床疗效和安全性观察研究

Public title:

Clinical efficacy and safety observation of Bushen Zhuangjin Decoction in the treatment of early and middlestage knee osteoarthritis

注册题目简写:

English Acronym:

研究课题的正式科学名称:

基于转录组学的加味补肾壮筋汤治疗膝骨关节炎作用机制研究

Scientific title:

Study on the mechanism of Jiawei Bushen Zhuangjin Decoction in treating knee osteoarthritis based on transcriptomics

研究课题的正式科学名称简写:

Scientific title acronym:

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

韩小飞

研究负责人:

韩小飞

Applicant:

Xiaofei Han

Study leader:

Xiaofei Han

申请注册联系人电话:

Applicant telephone:

15837131696

研究负责人电话:

Study leader's telephone:

15837131696

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

15837131696@139.com

研究负责人电子邮件:

Study leader's E-mail:

15837131696@139.com

申请单位网址(自愿提供):

Study leader's website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website
(voluntary supply):

申请注册联系人通讯地址:

河南省郑州市金水区东风路2号河南中医药大学东风路校区

研究负责人通讯地址:

河南省郑州市金水区东风路2号河南中医药大学东风路校区

Applicant address:

Dongfeng Road Campus, Henan University of Chinese Medicine, No. 2 Dongfeng Road, Jinshui District, Zhengzhou City, Henan Province

Study leader's address:

Dongfeng Road Campus, Henan University of Chinese Medicine, No. 2 Dongfeng Road, Jinshui District, Zhengzhou City, Henan Province

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

河南中医药大学

Applicant's institution:

Henan University of Chinese Medicine

是否获伦理委员会批准:

Approved by ethic committee:

伦理委员会批件文号:

Approved No. of ethic committee:

医院伦理审第(1537-01)号

伦理委员会批件附件:

Approved file of Ethical Committee:

View

批准本研究的伦理委员会名称:

河南省中医院(河南中医药大学第二附属医院)伦理委员会

Name of the ethic committee:

Ethics Committee of Henan Provincial Hospital of Traditional Chinese Medicine (the Second Affiliated Hospital of Henan University of Chinese Medicine)

伦理委员会批准日期:

Date of approved by ethic committee:

2024/1/3 0:00:00

伦理委员会联系人:

胡仕祥

Contact Name of the ethic committee:

Xiangshi Hu

伦理委员会联系地址:

河南省郑州市金水区东风路2号河南中医药大学东风路校区

Contact Address of the ethic committee:

Dongfeng Road Campus, Henan University of Chinese Medicine, No. 2 Dongfeng Road, Jinshui District, Zhengzhou City, Henan Province

伦理委员会联系人电话:

Contact phone of the ethic committee:

0371-60903768

伦理委员会联系人邮箱:

Contact email of the ethic committee:

zcaiy0928@163.com

研究实施负责(组长)单位:

河南中医药大学

Primary sponsor:

Henan University of Chinese Medicine

研究实施负责(组长)单位地址:

河南省郑州市郑东新区金水东路156号

Primary sponsor's address:

156 Jinshui East Road, Zhengdong New District, Zhengzhou City, Henan Province

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

河南省

市(区县):

Country:

China

Province:

Henan Province

City:

单位(医院):

河南省中医院

具体地址:

河南省郑州市金水区东风路2号

Institution
hospital:

Henan Provincial Hospital of Traditional Chinese Medicine

Address:

2 Dongfeng Road, Jinshui District, Zhengzhou City, Henan Province

经费或物资来源:

河南省高校科技创新团队支持计划

Source(s) of funding:

Henan University science and technology innovation team support plan

研究疾病:

膝骨关节炎

研究疾病代码:

Target disease:

knee osteoarthritis

Target disease code:

研究类型:

Study type:

观察性研究

Observational study

研究设计:

Study design:

单臂

Single arm

研究所处阶段:

Study phase:

探索性研究/预试验

Pilot clinical trial

研究目的:

观察加味补肾壮筋汤治疗早中期膝骨关节炎患者的临床疗效和安全性

Objectives of Study:

To observe the clinical efficacy and safety of Jiawei Bushenzhuangjin decoction in the treatment of patients with early and middle stage knee osteoarthritis

药物成份或治疗方案详述:

Description for medicine or protocol of treatment in detail:

纳入标准:

1) 符合KOA诊断标准的患者(单侧或双侧); 2) 患者年龄段在50-70岁之间,男女不限; 3) 膝关节X线K-L分级属于Ⅱ-Ⅲ级; 4) KOA分期属于早中期; 5) 患者自身基础情况良好,适合药物治疗,且不具备明显手术指征的患者; 6) 患者依从性较好,签署知情同意书。

Inclusion criteria

1) Patients who meet the diagnostic criteria for KOA (unilateral or bilateral); 2) Patients aged between 50 and 70 years old, both male and female; 3) The X-ray K-L grade of the knee joint belongs to grade II-III; 4) KOA stage belongs to the early and middle stages; 5) Patients with good basic conditions, suitable for drug treatment, and no obvious indications of surgery; 6) The patient had good compliance and signed the informed consent.

排除标准:

1)近一周内服用过与治疗KOA的中药汤剂、中成药或其他西药; 2)入组前参与其他研究项目活动者; 3)合并膝关节肿瘤、结核、风湿、类风湿性关节炎、痛风性关节炎等疾病的患者; 4)曾做过膝关节置换术的患者; 5)妊娠或计划妊娠或哺乳期妇女; 6)合并有心、脑血管、造血系统严重原发病,精神疾病,恶性肿瘤,以及肝肾功能不全的患者; 7)正在参加影响本研究结果评价的其他临床试验者。

Exclusion criteria:

1) Have taken traditional Chinese medicine decoction, proprietary Chinese medicine or other Western medicine with KOA treatment in the past week; 2) Participants in other research projects before enrollment; 3) Patients with knee joint tumor, tuberculosis, rheumatism, rheumatoid arthritis, gouty arthritis and other diseases; 4) Patients who have undergone knee replacement; 5) Pregnant or planning to become pregnant or lactating women; 6) Patients with severe primary diseases of the heart, cerebrovascular and hematopoietic systems, mental diseases, malignant tumors, and liver and kidney dysfunction; 7) Participants in other clinical trials that affect the evaluation of the results of this study.

研究实施时间:

Study execute time:

From 2024-06-01

To      2025-06-01

征募观察对象时间:

Recruiting time:

From 2024-07-01

To      2024-12-31

干预措施:

Interventions:

组别:

试验组

样本量:

10

Group:

Experimental group

Sample size:

干预措施:

补肾壮筋汤

干预措施代码:

Intervention:

Bushen Zhuangjin Decoction

Intervention code:

样本总量 Total sample size : 10

研究实施地点:

Countries of recruitment
and research settings:

国家:

中国

省(直辖市):

河南省

市(区县):

Country:

China

Province:

Henan Province

City:

单位(医院):

河南省中医院

单位级别:

三级甲等

Institution/hospital:

Henan Provincial Hospital of Traditional Chinese Medicine

Level of the institution:

Third class first class

测量指标:

Outcomes:

指标中文名:

生活质量评分

指标类型:

次要指标

Outcome:

Life quality score

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

肝功能

指标类型:

副作用指标

Outcome:

Liver function

Type:

Adverse events

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

心电图

指标类型:

副作用指标

Outcome:

Electrocardiogram

Type:

Adverse events

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

膝关节活动度

指标类型:

次要指标

Outcome:

Knee range of motion

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

视觉模拟评分

指标类型:

主要指标

Outcome:

Visual Analogue Scale/Score

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

WOMAC评分

指标类型:

主要指标

Outcome:

The Western Ontario and McMaster

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

中医证候积分

指标类型:

次要指标

Outcome:

TCM syndrome integral

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

肾功能

指标类型:

副作用指标

Outcome:

Renal function

Type:

Adverse events

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁

说明

Fate of sample 

Destruction after use

Note:

征募研究对象情况:

尚未开始

Not yet recruiting

年龄范围:

最小 50
Min age years
最大 70
Max age years

Recruiting status:

Participant age:

性别:

Gender:

男女均可

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

None

盲法:

Blinding:

是否共享原始数据:

IPD sharing:

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

2025年7月上传注册平台

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Uploaded to the registration platform in July 2025

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

1 数据的采集 1.1 研究者必须保证数据完整、真实、准确。 1.2 研究记录所有项目均需填写,不得空项、漏项(无记录的空格按要求填写)。 1.3 实验室检查项目齐全。 2 数据监查和录入 医生详细记录病程,将病程、医嘱单、各类检查单拍照上传数据管理系统。由课题组专人整理入电子平台。 课题组会委派专人做好病例信息录入的督促工作,每日检查、签字。 由统计单位数据管理员双份录入,如有疑问,由研究者对问题进行书面解答并签名,交回数据管理员,输入数据库。统计分析前,数据库将被锁定,不再作更改。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

1. Data collection 1.1 The researcher must ensure that the data is complete, true and accurate. 1.2 All items in the research record should be filled in, with no blank items or missing items (blank Spaces without records should be filled in as required). 1.3 Complete laboratory inspection items. 2. Data monitoring and input The doctor records the course of the disease in detail, takes pictures of the course of the disease, the doctor's order sheet, and all kinds of test sheets and uploads them to the data management system. The research team will arrange it into the electronic platform. The research group will assign special personnel to supervise the entry of case information, check and sign daily. The data manager of the statistical unit shall enter the data in two copies. If there is any doubt, the researcher shall answer the question in writing and sign it, return it to the data manager, and enter it into the database. Before statistical analysis, the database is locked and no changes are made.

数据管理委员会:

Data Managemen Committee:

Yes

研究计划书或研究结果报告发表信息
(杂志名称、期、卷、页,时间;或网址):

Publication information of the protocol/research results report
(name of the journal, volume, issue, pages, time; or website):

ITMCTR BJ-ICP:07032215-5 Tip: IE8 is recommended Use the system with widescreen display resolution above